SANTA BARBARA, Calif.,
Nov. 4, 2013 /PRNewswire/ -- VG
Life Sciences, Inc. is a publicly traded (VGLS) biotechnology
company focused on developing treatments for patients suffering
autoimmune and infectious diseases.
(Logo:
http://photos.prnewswire.com/prnh/20131031/LA07859LOGO)
VG Life Sciences, Inc. has contracted ITR Laboratories Canada,
Inc. to perform FDA IND enabling animal safety studies with its
patented peptide VG1177. The studies will address the optimum route
of administration and will provide key toxicological,
pharmacological, genotoxicological, and toxicokinetic data for IND
applications that VG Life Sciences, Inc. will submit for FDA
review.
The inventor of VG1177 is Dr. Karen
Newell Rogers, PhD at Texas A&M
University School of Medicine and Chief Scientist at VG Life
Sciences. "These animal safety studies mark an important step in
advancing VG1177 from technology to treatment, and will provide key
safety data in support of our coming clinical trials," said Dr.
Newell Rogers.
Results from the studies are expected to conclude by
July 2014.
"At our restructuring in July we identified three important
initiatives that we needed to complete this year: raise additional
capital, begin audited financials and start animal safety studies.
We are proud we completed all these goals in less than 4 months.
This sets the stage for key milestones in 2014," said John Tynan, VG Life Sciences' President and CEO.
"Thus we are pleased to announce the start of this important
pre-clinical study bringing us closer to monetize our intellectual
property as outlined in our July 2013
Letter to Shareholders."
The VG1177 peptide prevents the survival of pro-inflammatory
cells under conditions where inflammation is unwanted, thereby
allowing the body's natural containment systems to provide
protection from harm.
About ITR Laboratories Canada, Inc.
Montreal-based ITR Laboratories
Canada Inc. is a privately held contract research organization
specializing in non-clinical studies for pharmaceutical and
biotechnology companies. For more information visit
www.itrlab.com.
About VG Life Sciences Inc.
Santa Barbara, California-based
VG Life Sciences Inc., formerly known as Viral Genetics, is a
biotechnology company working on discovering and developing drug
therapies for infectious diseases, cancer and many autoimmune
diseases. VGLS controls over 50 US and international patents and
patents pending protecting its exclusive biotech platform
technologies. For more information and upcoming events, visit
www.vglifesciences.com or find VG Life Sciences, Inc. on Facebook,
Twitter, and LinkedIn.
Safe Harbor Statement and Forward-Looking Statements
This news release may contain forward-looking statements that
involve risks and uncertainties associated with financial
projections, milestone timelines, clinical development, regulatory
approvals and other risks described by VG Life Sciences from time
to time in its periodic reports. None of VG Life Sciences' drug
compounds are approved by the US FDA or by any comparable
regulatory agencies elsewhere in the world. Therefore, there can be
no assurance that the forward-looking statements included in this
release will prove to be accurate. In light of the significant
uncertainties inherent in the forward-looking statements included
herein, the forward-looking statements should not be regarded as a
representation by VG Life Sciences or any other person that the
objectives and plans of VG Life Sciences will be achieved.
Contact:
Alexandria Sumner, Director of
Corporate Communications
VG Life Sciences, Inc.
Phone: (805) 679-6763
Email: asumner@vglifesciences.com
SOURCE VG Life Sciences, Inc.